Order results by:
| Issue | Title | |
| Vol 10, No 1 (2018) | New drugs for anti-B-cell therapy of multiple sclerosis | Abstract similar documents |
| A. N. Boyko, N. Yu. Lashch, M. E. Guseva | ||
| "... for multiple sclerosis (MS) and the results of clinical trials of ocrelizumab, the first drug of this group ..." | ||
| Vol 17, No 3 (2025) | Switching from ocrelizumab to ofatumumab: key potential reasons based on real-world clinical practice | Abstract similar documents |
| A. N. Boyko, T. O. Simaniv, T. A. Prokopyeva, S. V. Petrov, M. V. Melnikov | ||
| "... necessitate switching from the better-known intravenous drug ocrelizumab to the subcutaneous agent ofatumumab ..." | ||
| Vol 11, No 1 (2019) | Experience with anti-B-cell therapy in the pathogenetic treatment of multiple sclerosis | Abstract PDF (Eng) similar documents |
| O. V. Boyko, S. V. Petrov, N. Yu. Lashch, M. R. Guseva, A. N. Boyko | ||
| "... therapy using ocrelizumab, an anti-CD20 monoclonal antibody. The drug is indicated for primary progressive ..." | ||
| Vol 11, No 3 (2019) | Clinical recommendations for the use of ocrelizumab in patients with multiple sclerosis | Abstract similar documents |
| A. N. Boyko, M. V. Davydovskaya, N. V. Khachanova, M. N. Zakharova, N. N. Spirin, E. V. Popova, V. M. Alifirova, Ya. V. Vlasov, S. A. Sivertseva, F. A. Khabirov, M. V. Shumilina, E. P. Evdoshenko | ||
| "... multiple sclerosis and primary progressive multiple sclerosis in the use of ocrelizumab. ..." | ||
| Online-first | Infusion anti-B-cell therapy in multiple sclerosis: a comparative analysis of agents within the same class | Abstract similar documents |
| A. N. Boiko, A. D. Kukushkina, S. V. Rogovsky | ||
| "... therapies, ocrelizumab currently holds a clinical advantage due to the breadth of real-world experience ..." | ||
| Vol 16 (2024): (Suppl. 2) | Experience with the use of cladribine tablets in real-life clinical practice: independent analysis of data from 12 Russian clinical centres | Abstract similar documents |
| A. N. Boyko, V. M. Alifirova, D. V. Pashkovskaya, E. I. Kuchina, S. A. Sivertseva, E. L. Turova, Z. A. Goncharova, O. Yu. Rudenko, Yu. Yu. Pogrebnova, F. A. Khabirov, T. I. Khaibullin, N. N. Babicheva, N. L. Khoroshilova, O. V. Dzundza, O. A. Soldatova, A. N. Belova, G. Е. Sheiko, A. Е. Makarova, N. G. Glavinskaya | ||
| "... therapies such as natalizumab and ocrelizumab is noteworthy. Both drugs are prescribed for aggressive types ..." | ||
| Vol 11, No 4 (2019) | Current requirements for studies of drugs for the pathogenetic treatment of multiple sclerosis | Abstract similar documents |
| A. N. Boyko, N. N. Spirin, Ya. V. Vlasov, M. N. Zakharova | ||
| "... More than 10 multiple sclerosis-modifying drugs (MSMDs) are widely used now. Novel MSMDs should ..." | ||
| Vol 9, No 1 (2017) | Clinical and epidemiological features of patients with multiple sclerosis in the Kursk Region | Abstract similar documents |
| V. B. Laskov, E. A. Logacheva, E. E. Tretyakova, M. A. Gridnev | ||
| "... and a range of prescribed disease-modifying drugs (DMDs) used to treat MS. Patients and methods. Data on 877 ..." | ||
| Vol 13, No 1S (2021): Спецвыпуск: рассеянный склероз | Attitude to reproduced disease modifying therapies in patients with relapsing-remitting multiple sclerosis: results of a medical and sociological study | Abstract similar documents |
| Ya. V. Vlasov, M. V. Churakov, E. V. Sineok, A. N. Boyko | ||
| "... of the most urgent in modern neurology. The number of patients and the cost of drugs are increasing, leading ..." | ||
| Vol 14, No 1S (2022): Спецвыпуск: рассеянный склероз | Ways to improve adherence to long-term injection therapy in multiple sclerosis using the example of pegylated interferon-β1a (sampeginterferon β-1a) | Abstract similar documents |
| A. N. Boyko | ||
| "... of the drug while maintaining its high efficiency. To illustrate this, the increase in adherence to treatment ..." | ||
| Vol 12, No 5 (2020) | Recommendations for switching patients with highly active multiple sclerosis from other disease modifying drugs for multiple sclerosis to cladribine tablets | Abstract similar documents |
| N. A. Totolyan, V. M. Alifirova, K. Z. Bakhtiyarova, A. N. Boyko, Ya. V. Vlasov, Z. A. Goncharova, M. N. Zakharova, D. S. Kasatkin, S. V. Kotov, A. I. Nilov, S. A. Sivertseva, A. A. Sokolova, N. N. Spirin, F. A. Khabirov, D. Paradnika | ||
| "... of a highly effective disease-modifying drug for MS (DMDMS), but also conditions for the timely and safe ..." | ||
| Vol 16 (2024): (Suppl. 2) | Analysis of the experience with once-weekly intramuscular administration of interferon beta-1a in the Russian population of patients with relapsing-remitting multiple sclerosis | Abstract similar documents |
| F. A. Khabirov, E. V. Granatov, A. Ya. Dykhanov, T. I. Khaibullin | ||
| "... SinnoVex is a drug from the group of bioanalogues of interferon beta-1a for intramuscular ..." | ||
| Vol 13, No 1S (2021): Спецвыпуск: рассеянный склероз | Current ethical issues of clinical trials of drugs for the pathogenetic therapy of multiple sclerosis in the context of the COVID-19 pandemic | Abstract similar documents |
| E. V. Ivashkova, A. M. Petrov, M. V. Votintseva, I. D. Stolyarov | ||
| "... клинических медицинских учреждений при проведении исследований новых методов терапии рассеянного склероза (РС ..." | ||
| Vol 16 (2024): (Suppl. 2) | Optimization of therapy in secondary progressive multiple sclerosis | Abstract similar documents |
| A. N. Boyko, S. K. Zyryanov, Ya. V. Vlasov | ||
| "... sclerosis (SPMS). The only drug that has proven its effectiveness in all types of SPMS (with exacerbations ..." | ||
| Vol 16 (2024): (Suppl. 2) | Results of tele-rehabilitation in patients with multiple sclerosis during 2020–2021 COVID-19 pandemic | Abstract similar documents |
| S. A. Sivertseva, K. S. Anfilofeva, A. V. Zotova, V. D. Chukreev, A. Yu. Belkina, L. I. Volkova, M. E. Guseva, A. N. Boyko | ||
| "... progressive nature. In addition to diseasemodifying drug therapy of MS patients require physical ..." | ||
| Vol 8, No 4 (2016) | GLATIRAMER ACETATE IS A FIRST-LINE DUAL-ACTION DRUG FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS | Abstract similar documents |
| T. E. Shmidt | ||
| "... in the pathogenesis of MS. The use of MS-modifying drugs (MSMDs) has led to a substantial reduction in the frequency ..." | ||
| Vol 12, No 1S (2020): Спецвыпуск: рассеянный склероз | Experience with cladribine tablets for highly active multiple sclerosis in everyday clinical practice | Abstract similar documents |
| S. V. Petrov, O. V. Boyko, A. N. Boyko | ||
| "... Cladribine tablets are a new drug for the immune reconstitution therapy of highly active multiple ..." | ||
| Vol 15 (2023): (Suppl. 1) | The evolution of interferon therapy in multiple sclerosis | Abstract similar documents |
| O. V. Boyko, N. F. Smirnova, A. N. Boyko | ||
| "... days and to reduce the probability of NAB to less than 1% of all treated patients. The first drug ..." | ||
| Vol 13, No 3 (2021) | Results of Expert Council meeting on modern principles of treatment optimization in patients with relapsing-remitting multiple sclerosis using anti-CD20 monoclonal antibody | Abstract similar documents |
| A. N. Boyko, N. V. Khachanova, D. S. Korobko, D. S. Kasatkin, Ya. V. Vlasov, E. P. Evdoshenko, E. V. Popova, K. Z. Bakhtiyarova, S. A. Sivertseva | ||
| "... consensus statement on different drugs of this class in the MS treatment. In addition, the possibilities ..." | ||
| Vol 7, No 1 (2015) | Non-biological complex drugs and their analogues in the pathogenetic therapy of multiple sclerosis: Issues of efficacy and safety in clinical use | Abstract similar documents |
| I. D. Stolyarov, A. M. Petrov, M. V. Votintseva, I. G. Nikiforova | ||
| "... The paper generalizes the experience with one of the main original drugs for the treatment ..." | ||
| Vol 8, No 4 (2016) | USE OF DIMETHYL FUMARATE IN THE TREATMENT OF MULTIPLE SCLEROSIS: CLINICAL AND ECONOMIC ANALYSIS | Abstract similar documents |
| V. R. Mkrtchyan, L. V. Brylev, I. A. Shpak, A. M. Sergeev | ||
| "... and fingolimod. Among first-line oral drugs, dimethyl fumarate was shown to be superior to teriflunomide ..." | ||
| Vol 7, No 3 (2015) | Pharmacoeconomic analysis of the use of first- and second-line drugs in the treatment of multiple sclerosis | Abstract similar documents |
| V. R. Mkrtchyan, L. V. Brylev, O. V. Davydova, A. V. Belyanin, I. A. Shpak, A. M. Sergeev | ||
| "... drugs in the treatment of multiple sclerosis through cost, cost-effectiveness, and budget impact ..." | ||
| Vol 12, No 3 (2020) | Recommendations for the use of cladribine tablets for the pathogenetic treatment of patients with highly active multiple sclerosis | Abstract similar documents |
| K. Z. Bakhtiyarova, A. N. Boyko, Ya. V. Vlasov, Z. A. Goncharova, M. V. Davydovskaya, M. N. Zakharova, N. A. Malkova, A. I. Nilov, S. A. Sivertseva, N. N. Spirin, N. A. Totolyan, F. A. Khabirov, M. V. Shumilina | ||
| "... -modifying drugs (MSMDs) or there is ≥1 exacerbation and corresponding activity signs revealed by MRI during ..." | ||
| Vol 15, No 6 (2023) | Ofatumumab – the first fully human monoclonal antibody approved for the treatment of multiple sclerosis | Abstract similar documents |
| E. V. Popova | ||
| "... , and sometimes physicians encounter problems selecting a drug for therapy when considering patients ..." | ||
| Vol 8, No 1 (2016) | Multiple sclerosis-related fatigue and possibilities of its correction | Abstract similar documents |
| N. Yu. Lashch, A. N. Boiko | ||
| "... and with the administration of some drugs. Special tests and scales are used to objectify the degree of fatigue. The most ..." | ||
| Vol 15, No 6 (2023) | Russian-Belarusian Expert Council “New opportunities in the treatment of patients with multiple sclerosis” (October 1, 2023). Main conclusions of the first meeting | Abstract similar documents |
| A. N. Boyko, V. V. Vashchilin, O. V. Boyko, A. G. Bunyak, D. S. Kasatkin, D. S. Korobko, S. I. Kulikova, N. V. Mazgo, N. V. Makovskaya, S. A. Sivertseva, I. V. Smagina, T. N. Chernukha | ||
| "... , special attention was paid to two new Russian original drugs, modifying the course of MS. The place ..." | ||
| Online-first | The first experience with the use of ofatumumab for the treatment of pediatric multiple sclerosis in real-life clinical practice in Russia. A case series | Abstract similar documents |
| E. D. Kuzminykh, V. M. Lebedev, V. E. Senchenko, M. S. Cherepyansky, V. A. Gonchar, D. S. Korobko | ||
| "... remission during the six-month use of the drug. In the second observation, a 17-year-old female patient ..." | ||
| Vol 17, No 1 (2025) | The first experience with the use of ofatumumab for the treatment of pediatric multiple sclerosis in real-life clinical practice in Russia. A case series | Abstract similar documents |
| E. D. Kuzminykh, V. M. Lebedev, V. E. Senchenko, M. S. Cherepyansky, V. A. Gonchar, D. S. Korobko | ||
| "... remission during the six-month use of the drug. In the second observation, a 17-year-old female patient ..." | ||
| Vol 17, No 3 (2025) | Multiple sclerosis associated with adalimumab: a case report and systematic review | Abstract similar documents |
| A. A. Tappakhov, T. Ya. Nikolaeva, N. Yu. Gorokhova, L. T. Okoneshnikova, A. N. Ylakhova, E. E. Konnikova | ||
| "... controversial, although there is a limited number of studies addressing the influence of immunomodulatory drugs ..." | ||
| Vol 13, No 1S (2021): Спецвыпуск: рассеянный склероз | Comparison of medical and social characteristics and quality of life of patients with primary- and secondary-progressive multiple sclerosis | Abstract similar documents |
| Ya. V. Vlasov, N. G. Polyarnaya, A. N. Boyko | ||
| "... , there is a major problem in providing MS centers with effective drugs to treat both disease courses. When QoL ..." | ||
| Vol 16 (2024): (Suppl. 2) | Sampeginterferon beta-1a in clinical practice | Abstract similar documents |
| I. A. Sokolova, O. S. Kornakova, E. V. Sokolova | ||
| "... ) into clinical practice can improve treatment outcomes. Interferon beta drugs are commonly used as DMTs. Among ..." | ||
| Vol 12, No 1S (2020): Спецвыпуск: рассеянный склероз | Polymorphic variants in the PVT1 locus affect multiple sclerosis severity | Abstract PDF (Eng) similar documents |
| I. S. Kiselev, M. S. Kozin, N. M. Baulina, G. V. Pavlova, A. N. Boyko, O. G. Kulakova, O. O. Favorova | ||
| "... . The investigation enrolled 468 Russian MS patients who did not take immunomodulating drugs before blood testing ..." | ||
| Vol 13, No 1 (2021) | New possibilities of siponimod therapy in patients with secondary progressive multiple sclerosis | Abstract similar documents |
| D. S. Kasatkin, N. V. Khachanova, V. M. Alifirova, A. N. Boyko, K. Z. Bakhtiyarova, Ya. V. Vlasov, M. V. Davydovskaya, E. P. Evdoshenko, S. A. Sivertseva | ||
| "... Процесс нейродегенерации при рассеянном склерозе (РС) остается актуальной проблемой современной ..." | ||
| Vol 17, No 1 (2025) | Aggressive multiple sclerosis in the Republic of Bashkortostan | Abstract similar documents |
| K. Z. Bakhtiyarova, U. Sh. Kuzmina, O. V. Lyutov, I. D. Talipova, N. F. Akhmetgaleeva, T. R. Galiullin, M. A. Kutlubaev | ||
| "... Лечение больных с агрессивным рассеянным склерозом (РС), характеризующимся резким ..." | ||
| Vol 10, No 1S (2018): СПЕЦВЫПУСК: ЭПИЛЕПСИЯ | Generic substitutions of antiepileptic drugs: Is it possible to put an end to the discussion? | Abstract similar documents |
| E. A. Ushkalova, S. K. Zyryanov, K. E. Zatolochina | ||
| "... an epileptic patient may be switched from brand-name to generic antiepileptic drugs. The paper gives data ..." | ||
| Vol 12, No 1 (2020) | Association of BAFF gene polymorphisms with multiple sclerosis progression | Abstract PDF (Eng) similar documents |
| I. V. Smagina, S. A. Elchaninova, A. S. Palashchenko | ||
| "... . The investigation results will be able to predict the efficiency of MS therapy with anti-BAFF drugs and to identify ..." | ||
| Vol 7, No 1S (2015): Special issue "Epilepsy" | Epilepsy in patients with multiple sclerosis: specific features of diagnosis and therapy | Abstract similar documents |
| Yu. A. Belova, T. I. Yaukushina, I. G. Rudakova, S. V. Kotov | ||
| "... untreated for MS; 7 took MS-modifying drugs: interferonβ1a (n=2) or glatiramer acetate (n=5). The course ..." | ||
| Vol 15 (2023): (Suppl. 1) | Prolonged observation after the use of cladribine in multiple sclerosis: efficacy and safety | Abstract similar documents |
| A. D. Kukushkina, A. N. Boyko | ||
| "... of a greater number of highly effective drugs that alter the course of MS (disease-modyfyung therapies, DMTs ..." | ||
| Vol 17, No 3 (2025) | Curcumin as add-on therapy in patients with multiple sclerosis showing a suboptimal response to first-line disease-modifying therapies: clinical outcomes and in vitro data | Abstract similar documents |
| A. D. Kukushkina, V. S. Rogovskii, E. V. Ponevezhskaia, E. V. Lysogorskaia, A. N. Boyko | ||
| "... to the development of disease-modifying therapies (DMTs), which are classified into first- and second-line drugs ..." | ||
| Vol 13, No 1S (2021): Спецвыпуск: рассеянный склероз | Clinical and epidemiological characteristics of multiple sclerosis in students in the Republic of Bashkortostan | Abstract similar documents |
| A. V. Tukhvatullin, U. Sh. Kuzmina, N. F. Utyagulova, R. F. Talisov, V. A. Vakhitov, K. Z. Bakhtiyarova | ||
| "... В последние годы фиксируется расширение возрастного диапазона манифестации рассеянного склероза ..." | ||
| Vol 14, No 1 (2022) | Experience with cladribine tablets for highly active multiple sclerosis in real clinical practice | Abstract similar documents |
| S. V. Petrov, O. V. Boyko, A. N. Boyko | ||
| "... таблетках в качестве средства терапии иммунной реконституции высокоактивного рассеянного склероза (ВАРС ..." | ||
| Vol 8, No 2 (2016) | Histological classification of mesial temporal sclerosis | Abstract similar documents |
| D. V. Dmitrenko, M. A. Stroganova, N. A. Shnaider, G. P. Martynova, K. A. Gazenkampf, A. V. Dyuzhakova, Yu. S. Panina | ||
| "... Mesial temporal sclerosis (MTS) is the most common histopathology occurring in patients with drug ..." | ||
| Vol 13, No 2 (2021) | COVID-19 vaccination guidelines for patients with multiple sclerosis | Abstract similar documents |
| N. V. Khachanova, N. A. Totolyan, Ya. V. Vlasov, S. A. Sivertseva, M. V. Davydovskaya, E. P. Evdoshenko, A. P. Prodeus, M. N. Zakharova, N. N. Spirin, A. N. Boyko | ||
| "... больным рассеянным склерозом (РС). Авторы консенсуса на основе анализа большого числа отечественных и ..." | ||
| Vol 1, No 3-4 (2009) | RUSSIAN OBSERVATIONAL SURVEY OF THE SHORT-TERM EFFICACY AND TOLERABILITY OF SUSTAINED-RELEASE SODIUM VALPROATE (DEPAKINE CHRONOSPHERA®) AS A FIRST-LINE DRUG IN THE TREATMENT OF EPILEPSY | Abstract similar documents |
| E. D. Belousova, A. Yu. Ermakov | ||
| "... antiepileptic drugs (AED). The follow-up lasted at least 2 months. Results. The most common reason for using ..." | ||
| Vol 5, No 1 (2013) | Epilepsy and pregnancy: current therapeutic tactics | Abstract similar documents |
| Pavel Nikolayevich Vlasov, V A Karlov, V A Petrukhin | ||
| Vol 9, No 1S (2017): SPECIAL ISSUE: EPILEPSY | Drug interchangeability: Clinical efficacy and safety | Abstract similar documents |
| S. K. Zyryanov, S. B. Fitilev, I. I. Shkrebneva, A. V. Vozzhaev | ||
| "... The paper deals with the problem of the interchangeability of brand-name and generic drugs ..." | ||
| Vol 6, No 1S (2014): Special issue "Epilepsy" | Intravenous Antiepileptic Drugs in Russia | Abstract similar documents |
| P. N. Vlasov | ||
| "... Launching four intravenous antiepileptic drugs: valproate (Depakene and Convulex), lacosamide ..." | ||
| Vol 11, No 4 (2019) | New possibilities for the therapy of secondary progressive multiple sclerosis | Abstract similar documents |
| A. M. Petrov, E. V. Ivashkova, I. D. Stolyarov | ||
| "... . Siponimod did not pose a higher risk for developing malignant neoplasms. The drug reduces the risk ..." | ||
| Vol 15 (2023): (Suppl. 1) | The place of virtual reality in the rehabilitation of patients with multiple sclerosis | Abstract similar documents |
| Iu. E. Korzhova, A. A. Fuks, A. S. Klochkov, A. E. Khizhnikova, N. A. Suponeva, M. N. Zakharova | ||
| "... an active lifestyle, mostly in young adults. Physical activity, along with drug therapy, is an essential ..." | ||
| Vol 13, No 6 (2021) | Generic drugs: benefit/risk ratio | Abstract similar documents |
| E. A. Ushkalova, S. K. Zyryanov, I. A. Gopienko | ||
| "... of original and generic drugs, and types of their equivalence, as well as problems with generics in clinical ..." | ||
| Vol 14, No 1S (2022): Спецвыпуск: рассеянный склероз | Results of a study of the quality of life in patients with highly active multiple sclerosis in Russia | Abstract similar documents |
| A. N. Boiko, K. Z. Bakhtiyarova, M. A. Sherman, Z. A. Goncharova, I. V. Smagina, T. I. Khaibullin, N. N. Babicheva, N. N. Spirina, I. A. Yampolskaya-Gosteva, I. A. Sokolova, I. V. Greshnova, V. E. Nikitenkova, I. G. Lukashevich, A. V. Inzhinova, N. A. Malkova, D. S. Korobko, O. V. Boyko, I. S. Lozovskaya | ||
| "... Рассеянный склероз (РС) – хроническое аутоиммунное воспалительное демиелинизирующее и ..." | ||
| Vol 16 (2024): (Suppl. 2) | Multifactorial model of predictors of the development of depressive disorders in multiple sclerosis: a prospective longitudinal study | Abstract PDF (Eng) similar documents |
| K. V. Gubskaia, Yа. V. Malygin, A. Yu. Aleksandrova | ||
| "... Депрессией страдают до 50% больных рассеянным склерозом (РС). Цель исследования – разработать ..." | ||
| Vol 5, No 1S (2013): Special issue "Epilepsy" | The effect of antiepileptic drugs on cognitive functions | Abstract similar documents |
| A. S. Kotov | ||
| "... effects of antiepileptic drugs. Their cognitive effects are one of the major problems affecting ..." | ||
| Vol 5, No 1S (2013): Special issue "Epilepsy" | Effect of drug formulation on the treatment of epilepsy | Abstract similar documents |
| S. G. Burd | ||
| "... The paper describes a trial dealing with the effect of the formulation of an antiepileptic drug ..." | ||
| Vol 14, No 2 (2022) | Changes in expression of miRNAs from the DLK1-DIO3 locus are characteristic of relapsing-remitting multiple sclerosis regardless of the disease activity | Abstract similar documents |
| N. M. Baulina, A. R. Kabaeva, A. N. Boyko, O. O. Favorova | ||
| "... in remission who did not receive immunomodulatory drugs, and 20 healthy individuals. Results and discussion ..." | ||
| Vol 9, No 1S (2017): SPECIAL ISSUE: EPILEPSY | Intellectual development of children born to mothers with epilepsy | Abstract similar documents |
| A. V. Yakunina, I. E. Poverennova, V. A. Kalinin, S. A. Ananyeva | ||
| "... groups of children. The comparison of the IQ scores in children who did not take antiepileptic drugs ..." | ||
| Vol 7, No 3 (2015) | Efficiency of epilepsy treatment in the Moscow Region under the present-day conditions of drug provision | Abstract similar documents |
| Irina Gennadyevna Rudakova, Yu. A. Belova | ||
| "... –2014 due to drug provision-related changes: the use of antiepileptic drugs (AEDs) in accordance ..." | ||
| Vol 5, No 1 (2013) | Thoracic spine pain | Abstract similar documents |
| Aleksey Ivanovich Isaikin, A V Kavelina | ||
| "... for thoracalgia includes a combination of non-drug and drug therapies. The cyclooxygenase 2 inhibitor meloxicam ..." | ||
| Vol 4, No 1 (2012) | Higher psychic dysfunctions in adult patients with epilepsy: role of antiepileptic therapy | Abstract similar documents |
| Kira Vladimirovna Voronkova, O A Pylayeva, I A Buchneva, T M Akhmedov | ||
| "... , including the use of antiepileptic drugs. Possible correction options are given for higher psychic sphere ..." | ||
| Vol 4, No 1 (2012) | Antyhypertensive therapy-based secondary prevention of ischemic stroke | Abstract similar documents |
| Vladimir Anatolyevich Parfenov, S V Verbitskaya, Yu A Starchina | ||
| "... -controlled trials of the use of different antihypertensive drugs in patients with prior stroke or transient ..." | ||
| Vol 1, No 2 (2009) | BACK PAIN AND ITS TREATMENT | Abstract similar documents |
| E. V. Podchufarova | ||
| Vol 4, No 1S (2012): Special issue "Epilepsy" | New antiepileptic drugs, cost-efficacy analysis | Abstract similar documents |
| P. N. Vlasov, N. V. Orekhova, T. I. Konovalova | ||
| "... and cost-effectiveness of its therapy with the new antiepileptic drugs (AED): levetiracetam, lamotrigine ..." | ||
| Vol 15 (2023): (Suppl. 1) | Prospects for the use of curcumin as an additional treatment for multiple sclerosis | Abstract similar documents |
| V. S. Rogovskii, A. D. Kukushkina, A. N. Boyko | ||
| "... Рассеянный склероз (РС) – хроническое демиелинизирующее заболевание аутоиммунной природы. Терапия ..." | ||
| Vol 16 (2024): (Suppl. 2) | Curcumin as an add-on therapy for multiple sclerosis in patients receiving interferon-beta therapy | Abstract similar documents |
| A. D. Kukushkina, V. S. Rogovskii, E. V. Ponevezhskaya, E. V. Lysogorskaia, A. N. Boyko | ||
| "... В настоящее время актуальным является поиск средств для добавочной терапии рассеянного склероза ..." | ||
| Vol 16, No 3 (2024) | Experience of cladribine tablets usage in the treatment of multiple sclerosis in the Multiple Sclerosis Centre of the Khanty-Mansi Autonomous Area — Yugra | Abstract similar documents |
| A. A. Sokolova, L. I. Anischenko, L. S. Zemlyanushin, E. A. Rubtsova | ||
| "... Кладрибин — таблетированный препарат для лечения ремиттирующего рассеянного склероза (РРС ..." | ||
| Vol 16, No 4 (2024) | Aviandr is a new original drug for treating anxiety | Abstract similar documents |
| V. A. Parfenov | ||
| "... , so the search for new drugs is needed. One of the new drugs that have been shown to be effective ..." | ||
| Vol 15, No 4 (2023) | Pharmacokinetic parameters, safety and drug-drug interactions of mirtazapine and tizanidine, combined in the new original drug Dorsumio® | Abstract similar documents |
| A. S. Goncharov, A. V. Grigoriev, A. A. Globenko, I. S. Goncharov, K. A. Muratov, D. V. Yaroshenko, A. A. Sidorova, A. V. Kapashin, O. V. Kovchan, A. I. Bashkatova, M. A. Pasko | ||
| "... volunteers in comparison with Calixta®, a monocomponent drug (INN: Mirtazapine, filmcoated tablets, 30 mg ..." | ||
| Vol 9, No 1S (2017): SPECIAL ISSUE: EPILEPSY | Rationale for mono- versus polytherapy with antiepileptic drugs for patients with epilepsy | Abstract similar documents |
| L. V. Lipatova, T. V. Kapustina | ||
| "... with epilepsy after failure of monotherapy with a first antiepileptic drug (AED). When choosing alternative ..." | ||
| Vol 15, No 2 (2023) | Withdrawal of valproic acid during pregnancy in women with epilepsy | Abstract similar documents |
| H. I. Navumava, P. N. Vlasov, A. I. Prusakova, A. A. Usoltseva, N. A. Shnayder, D. V. Dmitrenko | ||
| "... - the drug was changed. The number of women with epilepsy taking VA during pregnancy has decreased from 38 ..." | ||
| Vol 10, No 3 (2018) | Comparative evaluation of the efficiency of a sumatriptan/dexketoprofen combination versus sumatriptan monotherapy in the treatment of a migraine attack | Abstract similar documents |
| K. V. Skorobogatykh, Yu. E. Azimova | ||
| "... filled out a questionnaire in which they indicated the time of attack onset, the time of drug intake ..." | ||
| 1 - 70 of 778 Items | 1 2 3 4 5 6 7 8 9 10 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
